Epigenomics AG Forms Medical Advisory Board for Colorectal Cancer Screening
High-profile board to support Epigenomics in development and commercialization of its colorectal cancer screening test in the U.S.
Epigenomics AG announced the formation of its colorectal cancer Medical Advisory board and the appointment of its first four members. The board will advise Epigenomics on important aspects of the clinical development and commercialization process of the colorectal cancer screening test in the US. The inaugural meeting of the board will be held on October 12, 2007 in Philadelphia, PA, U.S.A.
The members of the board include Douglas Rex, MD (Chancellor's Professor and Professor of Medicine at Indiana University School of Medicine), Philip S. Schoenfeld, M.D., M.Ed., M.Sc. (Associate Professor, Department of Internal Medicine, University of Michigan School of Medicine), Deborah Fisher, MD, MHS, (Assistant Professor of Medicine, Duke University), and Scott Ramsey, M.D., Ph.D., (Associate Professor of Medicine and Health Services, Associate Member, Cancer Prevention Research Program, Fred Hutchinson Cancer Research Center).
The four initial members represent a cross section of gastroenterologists with particular expertise in colonoscopy, colorectal cancer screening, evidence-based medicine, outcomes research, and health economic analysis. Epigenomics' Medical Advisory Board will support the company and its corporate partners through design of its prospective clinical validation study and ancillary studies, speaking on behalf of the application of DNA methylation technology to colorectal cancer screening in the U.S., advising on product positioning in the U.S.and support inclusion of blood screening assays into screening guidelines promulgated by US American professional societies.
Other news from the department people
